^
    Back
    Association details:
    Biomarker:PD-L1 underexpression
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ASCO.org
    Title:

    Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

    Published date:
    12/15/2022
    Excerpt:
    Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers....Recommendation 2.2….Pembrolizumab, platinum, and fluorouracil may be offered as first-line treatment for patients with recurrent or metastatic HNSCC with a CPS < 1
    Secondary therapy:
    5-fluorouracil
    DOI:
    10.1200/JCO.22.02328